Home Featured Page 286

Featured

Latest

Psilocybin for Cocaine Use Disorder: Peter Hendricks on a Trial Ten Years in the Making

Pα+ Psychedelic Bulletin #224: Reactions to Trump’s Psychedelics Executive Order, and What Comes Next; Pre-EO, DEA Poured Cold Water on Right to Try

God, Gabon, and Government: W. Bryan Hubbard on Ibogaine, the Executive Order, and What Comes Next

The Optimisation Problem: What Bryan Johnson’s 5-MeO-DMT Experiment Reveals About Psychedelics Going Mainstream

Novamind Partners with Merck for New Treatment-Resistant Depression Trial

Tryp Therapeutics Announces Provisional Patent Filing For Improved Administration of Psychedelics

atai Life Sciences AG Announces Equity Investment in and Strategic Partnership...

Psychedelic Capitalism and Other Myths: Is the Joke On Us?

Psychotic- vs. Psychedelic-Induced Hallucinations: A Closer Look

Bright Minds Biosciences Announces Closing of $25.9 Million Unit Offering

Cybin Progresses Two Psychedelic Investigational New Drug (“IND”) Candidates and Announces...

Field Trip Health Ltd. Announces Closing of $95 Million Bought Deal...

Psyched Wellness Submits a Provisional Patent Application For AME-1

Algernon Pharmaceuticals Submits U.S. FDA Pre-IND Meeting Request for Psychedelic Drug...

EDITOR PICKS

Psilocybin for Cocaine Use Disorder: Peter Hendricks on a Trial Ten...

Pα+ Psychedelic Bulletin #224: Reactions to Trump’s Psychedelics Executive Order, and...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.